Search

Raloxifene HCl (RLX) is a BCS class - II drug, used in osteoporosis. For RLX liquisolid compacts (LSC), selection of non volatile liquid vehicle, carrier, coating material, super disintegrant were done and they were developed by using Propylene Glycol (PG): Polyethylene Glycol (PEG) 600 as a combination of non volatile liquid vehicles, Avicel PH101 as a carrier, Aeroperl 300 as coating material and Kyron T 314 as super disintegrant. The optimized batch was characterized by tests like flow property, content uniformity of mass, weight variation, tablet hardness, friability, disintegration time, XRD (X-ray diffraction) study, in vitro drug release test. The results of in vitro drug release study of RLX optimized batch illustrated a remarkable improvement in the dissolution rate as compared to Reference product (Ralista) and pure drug with other parameters of tablet. Accelerated stability study of the optimized batch was done for 3 months (at 25°C ± 2°C temperature and 40% ± 5% Relative humidity) and showed no significant change in appearance, drug content and in vitro drug release. This study concluded that LSC of RLX prove as one of the suitable approach for developing stable solid oral dosage form of poorly water soluble drug - RLX. [ABSTRACT FROM AUTHOR]